Navigation Links
Data on SEEK's Novel Immunotherapy for HIV Published in Virology Journal
Date:4/16/2013

LONDON, April 16, 2013 /PRNewswire/ --

 Antibody Treatment for HIV

SEEK, a privately-owned UK drug discovery group, announces that pre-clinical results on its HIV immunotherapy have been published in the peer-reviewed journal Virology Journal.  

SEEK's HIV immunotherapy triggers the immune system's cellular and antibody responses to selectively identify and kill HIV infected cells. The most exciting aspect of this therapy is that it directs the immune system towards short highly conserved regions of proteins produced by most circulating HIV strains. The triggered immune responses are highly effective both independently and in combination.

This opens up developing the antibody response into a monoclonal based therapy for treating HIV.

Monoclonal antibodies have revolutionised the treatment of cancer by improving outcomes and survival. In HIV/AIDS there is new interest in these products, as shown by the recent work of Duke University (USA) in developing a monoclonal antibody that prevents the virus from infecting cells. A monoclonal antibody capable of killing HIV-infected cells (potentially curative effect) would represent a radical new development in HIV therapy, which to this day relies on slowing down the virus rate of growth rather than in killing the cells that harbour it.  

By targeting a HIV component that is found only in infected cells and never in healthy cells, such monoclonal antibody therapy offers the potential of high specificity, reduced frequency of administration and minimal side-effects. This would represent a significant improvement over current anti-HIV drugs which require daily treatment and are associated with significant side effects.

Commenting on today's announcement, Gregory Stoloff , CEO of SEEK Group, said: "It is  very exciting to be at the forefront of this new approach which opens up HIV therapy to established and available antibody technology."

The manuscript: Olga Pleguezuelos, Gregory A Stoloff and Wilson Caparros-Wanderley , 'Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation', Virology Journal 2013, 10:107, can be found at the following URL:  

http://www.virologyj.com/content/10/1/107

In July 2011, SEEK announced the results of a Phase Ib/II study in humans which demonstrated that HIV immunotherapy showed a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single administration.

About SEEK

Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.

Additional information about SEEK is available on the Company's website located at http://www.seekacure.com

For more information please contact:

Gregory Stoloff , CEO, SEEK                  
Tel +44(0)20-7153-6570

M:Communications
Mary Clark / Amber Bielecka / Hollie Vile        
Tel +44(0)20-7920-2330
seek@mcomgroup.com


'/>"/>
SOURCE SEEK
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Searcy Denney Scarola Barnhart & Shipley PA Seeks Damages Caused by Recalled Product
2. American Academy of Pain Medicine Reacts to PROP Petition to the FDA that Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers
3. $1,000,000 Global B.R.A.I.N. Prize Seeks Applicants
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
6. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
7. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
8. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
11. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... GERMANTOWN, Md. , and GAITHERSBURG, Md. ... XON ), a leader in the engineering and ... health of the planet, today announced that it has entered ... (NASDAQ: GNVC ), a clinical-stage company and pioneer ... Intrexon intends to integrate and expand upon GenVec,s expertise ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
(Date:1/24/2017)...   QR Pharma , Inc., a privately ... for the treatment of Alzheimer,s, Parkinson,s and other ... world-class key opinion leaders to its Scientific Advisory ... previous roster of impressive advisors in order to ... development of the breakthrough mechanism of action of ...
Breaking Medicine Technology:
(Date:1/24/2017)... Mass. (PRWEB) , ... January 24, 2017 , ... ... company to visualize, detect, and eliminate cyber threats in real-time, today announced a ... This partnership will enable customers to monitor, respond and protect their critical information ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... Santa Rosa, CA (PRWEB) , ... January 24, 2017 , ... ... rates is good news for everyone and particularly good news for prostate cancer patients: ... from the diagnosis. , According to the report the cancer death rate has dropped ...
(Date:1/24/2017)... ... January 24, 2017 , ... A yellow fever outbreak in Brazil ... month. Yellow fever is primarily spread through contact with infected mosquitos. The outbreak has ... to prevent its spread. , According to multiple health organizations, the best way to ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Spiritual Vitamins: ... the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” is the creation ... Faith Publishing, Mathai Yohannan’s new book engages the mind and spirit in a ...
Breaking Medicine News(10 mins):